Kezar Life Sciences gains as kidney disorder drug shows promise in mid-stage study

Kezar Life Sciences

27/06/2022 22:46

** Shares of Kezar Life Sciences Inc  KZR.O  more than
double to $12.74 after market; among top pct gainers across all
three U.S. indexes
    ** Company reports positive results from mid-stage study
testing its lead drug, zetomipzomib, as a treatment for kidney
disorder lupus nephritis (LN)  urn:newsml:reuters.com:*:nBwc8LMZla 
    ** Kezar says zetomipzomib showed a favorable safety and
tolerability profile over 6-month treatment period in study with
adverse events being generally mild-to-moderate
    ** Company adds treatment benefit from drug remained and
deepened even 5 weeks after end of treatment period of 24 weeks 
    ** Lupus nephritis occurs when certain antibodies affect
kidneys' ability to filter out waste, potentially leading to
inflammation as well as blood and protein in the urine
    ** KZR is also testing zeptomipzomib as a potential
treatment for two inflammatory diseases - dermatomyositis and
polymyositis
    ** Up to Monday's close, KZR down 65.4% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788))